Edgewise Therapeutics (EWTX) provided information regarding the company’s relationship with Dr. Han Phan at Rare Disease Research. “On November 27, 2024, the U.S. Food and Drug Administration issued a warning letter to Dr. Phan based on a 2024 site inspection related to her work with another company. This warning letter is unrelated to any Edgewise clinical trial or data. None of the Edgewise clinical trials are the subject of the FDA’s warning letter. Edgewise has audited Dr. Phan’s site multiple times and believes that the data related to the Edgewise clinical trials at the site are being acquired and stored in accordance with FDA requirements,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise should be bought on weakness as ARCH not likely FDA focus, says Truist
- Edgewise falls after FDA posts Warning Letter to trial investigator
- Edgewise Therapeutics price target raised to $50 from $33 at Truist
- Edgewise Therapeutics initiated with an Outperform at Evercore ISI
- Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials